TABLE 1.
Demographic and baseline clinical characteristics
| Fremanezumab | Placebo (n = 117) | |||
|---|---|---|---|---|
| Monthly (n = 121) | Quarterly (n = 119) | Total (n = 240) | ||
| Age, years, mean (SD) | 44.4 (9.5) | 41.9 (10.1) | 43.1 (9.8) | 44.2 (10.7) |
| Country | ||||
| Japan, n (%) | 102 (84.3) | 101 (84.9) | 203 (84.6) | 98 (83.8) |
| Korea, n (%) | 19 (15.7) | 18 (15.1) | 37 (15.4) | 19 (16.2) |
| Body mass index, mean (SD) | 23.0 (4.0) | 22.5 (3.4) | 22.7 (3.7) | 22.8 (3.5) |
| Female sex, n (%) | 101 (83.5) | 101 (84.9) | 202 (84.2) | 100 (85.5) |
| Disease history | ||||
| Time since onset of migraine, mean year (SD) | 22.0 (12.9) | 18.3 (11.4) | 20.2 (12.3) | 19.4 (13.3) |
| Use of migraine‐preventive medications at baseline, yes, n (%) | 24 (19.8) | 23 (19.3) | 47 (19.6) | 22 (18.8) |
| n = 121 | n = 118 | n = 239 | n = 117 | |
|---|---|---|---|---|
| Disease characteristics during 28‐day preintervention period | ||||
| Number of days with headache of any severity and duration, mean (SD) | 11.0 (2.1) | 11.0 (2.5) | 11.0 (2.3) | 11.1 (2.5) |
| Number of headache days of at least moderate severity, mean (SD) | 7.6 (2.5) | 7.5 (2.8) | 7.5 (2.6) | 8.0 (2.8) |
| Number of migraine days, mean (SD) | 8.6 (2.5) | 8.7 (2.5) | 8.7 (2.5) | 9.0 (2.8) |
| Use of any acute headache medications, yes, n (%) | 120 (99.2) | 117 (98.3) | 237 (98.8) | 117 (100.0) |
| Use of migraine‐specific acute headache medicationsa, yes, n (%) | 115 (95.0) | 110 (92.4) | 225 (93.8) | 114 (97.4) |
a
Triptans and ergot compounds.